Neuralstem Inc (CUR) Jumps 17.54% on February 16

Equities Staff |

Neuralstem Inc (CUR) was among the biggest gainers on the Russell 2000 for Tuesday February 16 as the stock popped 17.54% to $0.81, representing a gain of $0.121 per share. Some 248,876 shares traded hands on 327 trades, compared with an average daily volume of 314,179 shares out of a total float of 91.79 million. The stock opened at $0.69 and traded with an intraday range of $0.85 to $0.69.

After today's gains, Neuralstem Inc reached a market cap of $74.44 million. Neuralstem Inc has had a trading range between $3.92 and $0.52 over the last year, and it had a 50-day SMA of $0.92 and a 200-day SMA of $1.38.

Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.

Neuralstem Inc is based out of Germantown, MD and has some 31 employees. Its CEO is I. Richard Garr.

For a complete fundamental analysis analysis of Neuralstem Inc, check out Equities.com’s Stock Valuation Analysis report for CUR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…